Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 8/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19736689 | 0.83 | PIK3CA (0.45) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL20461927 | 0.80 | PIK3CA (0.60) | PIK3CAPIK3CBPIK3CGPIK3CDEGFR | |
| SCHEMBL19286558 | 0.78 | PIK3CD (0.53) | PIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL12702954 | 0.78 | PIK3CA (0.62) | PIK3CAPIK3CBPIK3CGPIK3CDEGFR | |
| SCHEMBL20747621 | 0.78 | PIK3CA (0.36) | PIK3CAPIK3CBPIK3CGPIK3CDEGFR | |
| SCHEMBL458986 | 0.77 | PIK3CA (0.60) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL115870 | 0.77 | PIK3CA (0.69) | PIK3CAPIK3CBPIK3CGPIK3CDEGFR | |
| SCHEMBL15652472 | 0.74 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGPIK3CDEGFR | |
| SCHEMBL17946826 | 0.74 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGPIK3CDEGFR | |
| SCHEMBL21083414 | 0.73 | L3MBTL1 (0.46) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | PIK3CA 6/4885PIK3CB 16/4885PIK3CG 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.